title: SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia.
abstract: Precursor B-acute lymphoblastic leukaemias (pre-B ALLs) comprise the majority of ALLs and virtually all blasts express CD22 in the cytoplasm and on the cell surface. In the present study (Southwestern Oncology Group S0910), we evaluated the addition of epratuzumab, a humanized monoclonal antibody against CD22, to the combination of clofarabine and cytarabine in adults with relapsed/refractory pre-B ALL. The response rate [complete remission and complete remission with incomplete count recovery] was 52%, significantly higher than our previous trial with clofarabine/cytarabine alone, where the response rate was 17%. This result is encouraging and suggests a potential benefit to adding epratuzumab to chemotherapy for ALL; however, a randomized trial will be needed to answer this question.
authors.affiliation: Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, The Cleveland Clinic, Cleveland, OH, USA.
authors.forename: Anjali S
authors.initials: AS
authors.lastname: Advani
authors.forename: Shannon
authors.initials: S
authors.lastname: McDonough
authors.forename: Steven
authors.initials: S
authors.lastname: Coutre
authors.forename: Brent
authors.initials: B
authors.lastname: Wood
authors.forename: Jerald
authors.initials: J
authors.lastname: Radich
authors.forename: Martha
authors.initials: M
authors.lastname: Mims
authors.forename: Margaret
authors.initials: M
authors.lastname: O'Donnell
authors.forename: Stephanie
authors.initials: S
authors.lastname: Elkins
authors.forename: Michael
authors.initials: M
authors.lastname: Becker
authors.forename: Megan
authors.initials: M
authors.lastname: Othus
authors.forename: Frederick R
authors.initials: FR
authors.lastname: Appelbaum
mesh_terms: D000227:Adenine Nucleotides / Q000008:administration & dosage / Q000009:adverse effects; D000328:Adult; D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology; D000951:Antigens, Neoplasm / Q000276:immunology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001087:Arabinonucleosides / Q000008:administration & dosage / Q000009:adverse effects; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology; D000077866:Clofarabine; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects; D064147:Febrile Neutropenia / Q000139:chemically induced; D005260:Female; D006323:Heart Arrest / Q000139:chemically induced; D006402:Hematologic Diseases / Q000139:chemically induced; D006801:Humans; D008297:Male; D008875:Middle Aged; D018365:Neoplasm, Residual; D015452:Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000235:genetics; D012008:Recurrence; D012074:Remission Induction; D012306:Risk; D016879:Salvage Therapy; D051918:Sialic Acid Binding Ig-like Lectin 2 / Q000276:immunology; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000227:Adenine Nucleotides; D061067:Antibodies, Monoclonal, Humanized; D000951:Antigens, Neoplasm; D001087:Arabinonucleosides; C497867:CD22 protein, human; D051918:Sialic Acid Binding Ig-like Lectin 2; D003561:Cytarabine; C448700:epratuzumab; D000077866:Clofarabine
keywords: CD22; Treatment; acute lymphocytic leukaemia; epratuzumab; relapse